Floatz logo

Cetuximab

ATC

C4 Therapeutics, Inc.monoclonal_antibodyPhase 1Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

14 Active assets in the ATC cohort.

Asset / SponsorPhaseRating
gsk1120212
Cancer Research UK
Phase 2/3B
Dabrafenib
Cancer Research UK
Phase 2/3B
Cobimetinib
Cancer Research UK
Phase 2/3B
VEMURAFENIB
Cancer Research UK
Phase 2/3CCC
Nivolumab
M.D. Anderson Cancer Center
Phase 2CCC

View all 24 →

Same molecule, other indications

Cetuximab is also rated in:

colon adenocarcinomaDormant
BB
Indicative ·
70 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
70 / 100
View asset →
rectal carcinomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →